Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205450 | 1.00 | SLC1A2 (0.56) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL25364958 | 0.91 | CYP1A2 (0.52) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL25363542 | 0.91 | CYP1A2 (0.52) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24113373 | 0.91 | CYP1A2 (0.52) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL2238814 | 0.90 | DPP4 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7876588 | 0.90 | DPP4 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| Hydrochloric Acid SCHEMBL25365192 | 0.90 | CYP1A2 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7873502 | 0.90 | DPP4 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL7876596 | 0.90 | DPP4 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 | |
| SCHEMBL197230 | 0.90 | DPP4 (0.50) | SLC1A2SLC1A1CYP1A2CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-104230900-B | Antiviral compound | 吉利德制药有限责任公司 | 2018-10-19 | — | — | CN | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-106588890-A | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-104211713-B | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-12 | — | — | CN | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102596936-A | Antiviral compounds | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SLC1A2 4696/4885SLC1A1 4071/4885CYP1A2 3826/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SLC1A2 4696/4885SLC1A1 4071/4885CYP1A2 3826/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SLC1A2 4696/4885SLC1A1 4071/4885CYP1A2 3826/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SLC1A2 4696/4885SLC1A1 4071/4885CYP1A2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.